ResultsHealthcare & Life Sciences
Redcliffe Labs revenue FY25: ₹419 crore
Redcliffe Labs reports 20% revenue growth in FY25
By Abha Lohia · Editor ·
Redcliffe Labs revenue
Redcliffe Labs reported revenue of ₹419 crore in FY25, as reported by expresshealthcare and Entrackr on 8 July 2025.
| Revenue (FY25) | ₹419 crore |
|---|
Redcliffe Labs: revenue and funding and every story →
Gurugram
- Redcliffe Labs offers diagnostic tests and health checkup packages across India
- FY25 operating revenue rose 20% to ₹419 crore; EBITDA loss narrowed to -21% from -38%
- The company aims for ₹560 crore revenue in FY26 and quarterly EBITDA positivity by H2 FY26
What happened
- Redcliffe Labs reported its financial results for the fiscal year ending March 2025 (FY25).
- The company's operating revenue grew 20% year-on-year to ₹419 crore from ₹350 crore in FY24.
- Its EBITDA loss (earnings before interest, taxes, depreciation and amortisation; a measure of operating profitability) improved from -38% of revenue in FY24 to -21% in FY25.
- The gross margin (revenue minus the direct cost of delivering services) was over 70% in FY25.
- Redcliffe Labs diagnosed over 2.5 million patients during the year.
- More than 70% of diagnostic volumes came from non-metro areas, and over 1.8 million samples were processed from Tier 2 and smaller cities.
- Customer growth in Tier 2+ cities was 27% in FY25.
Why it matters
- The results show Redcliffe Labs is narrowing losses while expanding its reach beyond big cities.
- The company's focus on non-metro markets differentiates it from many competitors that concentrate on urban centres.
- Redcliffe Labs has raised $113 million to date, including a $42 million Series C led by LeapFrog.
- It acquired Bengaluru-based Celara Diagnostics for $7 million to strengthen its presence.
The business
- Redcliffe Labs operates 80+ self-owned labs and claims the widest home sample collection network in India.
- It has 2,000+ collection centres and 1,500+ trained phlebotomists (professionals who draw blood).
- Diagnostic services contributed over 95% of FY25 revenue; the rest came from product sales and other income.
- The company offers doctor-curated health checkup packages, smart reports with colour-coded insights, expert consultation, AI assistance, and personalised diet plans.
- It also runs Femcliffe, India's first she-centric diagnostic platform, and GeneCliffe genetic testing packages.
- Redcliffe Labs guarantees 100% report accuracy or money back and processes samples at certified labs with reports verified by MD pathologists.
The founders
In numbers
₹419 croreOperating revenue · FY25
₹350 croreOperating revenue · FY24
20%Revenue growth · FY25
-21%EBITDA margin · FY25
-38%EBITDA margin · FY24
over 70%Gross margin · FY25
2.5 millionPatients diagnosed · FY25
1.8 millionSamples from Tier 2+ cities · FY25
27%Customer growth in Tier 2+ cities · FY25
$113 millionTotal raised to date
What happens next
- Redcliffe Labs targets ₹560 crore in revenue for FY26.
- It aims for a gross margin of 74-75% in FY26.
- The company forecasts quarterly EBITDA positivity by the second half of FY26 (H2 FY26).
- It plans to serve 150+ cities and scale to 100+ labs and 220+ cities by the end of FY26.
- By FY28, it aims to reach over 300 cities with 150 labs through organic expansion and acquisitions.
Earlier rounds
- Series C · $42 million · led by LeapFrog
Up against
Thyrocare (PharmEasy-owned)Tata 1mgHealthians
Words to know
- EBITDA
- Earnings before interest, taxes, depreciation and amortisation; a measure of a company's operating profitability.
- Gross margin
- Revenue minus the direct cost of delivering services, expressed as a percentage of revenue.
- Non-metro areas
- Cities and towns that are not among India's largest metropolitan regions.
- Phlebotomist
- A healthcare professional trained to draw blood from patients for medical testing.
The numbers around it
Redcliffe Labs has 4 funding rounds in StopDown's archive, $115 Mn raised in all.
| When | Round | Amount | Led by |
|---|---|---|---|
| 17 September 2024 | Series C | $42M | IFU (Denmark's Investment Fund for Developing Countries) |
| 13 August 2023 | growth | $80 million | |
| 29 September 2022 | Series B | $100-125 million | |
| 6 May 2022 | Series B | $61M | LeapFrog Investments |
Other articles talking about it
Terms in this story
- EBITDA: EBITDA is earnings before interest, tax, depreciation and amortisation, a measure of operating profit before financing and accounting charges. It is not the same as net profit. In Indian startup results, check whether EBITDA includes ESOP costs, since adjusted versions often leave them out.
- Revenue from operations: Revenue from operations is what a company earns from its main business. Total income adds other income, such as interest on cash. When Indian outlets report different revenue for the same startup and year, they are often quoting one of these two lines.
- Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.
- Profitability: Profitable can mean five different things in a startup headline: profit after tax, positive EBITDA, positive adjusted EBITDA, positive cash flow or profit on each order. Only the first is a profit in the full accounting sense. Always check which one a story means.
Read next
FundingRedcliffe Lifetech raises $61 million Series BRedcliffe Lifetech is an omnichannel diagnostics platform offering 3,500+ pathology and genetic testsFundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centres
Everything on Redcliffe Labs → · All startup news on 8 July 2025 →
Is this Redcliffe Labs? Get your “Featured on StopDown” badge →